Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCP-lenalidomide
- Development stage
- Preclinical
- Lead developer
- Nexus Alliance Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
SCP-lenalidomide is a preclinical small molecule candidate being developed by Nexus Alliance Biopharmaceuticals for the treatment of glioblastoma. The drug utilizes the company's proprietary Self-Correcting Polymer (SCP) technology to formulate lenalidomide, an established immunomodulatory drug (IMiD). Lenalidomide acts as a molecular glue that binds to cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex. This binding event modifies the substrate specificity of the ligase, leading to the recruitment, ubiquitination, and subsequent proteasomal degradation of specific transcription factors, most notably Ikaros (IKZF1) and Aiolos (IKZF3). In glioblastoma, this SCP-formulated version is intended to optimize the delivery and therapeutic efficacy of lenalidomide, potentially enhancing its anti-tumor and anti-angiogenic properties within the central nervous system.
- Brand names
- RevlimidLenalidomide Accord
- Other names
- lenalidomide
02
Targets
CK1α (Casein kinase I alpha)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on SCP-lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCP-lenalidomide.